N4 Pharma Plc (AIM:N4P)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.502
-0.023 (-4.38%)
Mar 6, 2026, 3:21 PM GMT
-4.38%
Market Cap 4.37M
Revenue (ttm) 7.07K
Net Income (ttm) -1.10M
Shares Out 832.28M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 291,007
Average Volume 941,205
Open 0.550
Previous Close 0.525
Day's Range 0.502 - 0.550
52-Week Range 0.350 - 1.000
Beta 0.29
RSI 54.37
Earnings Date Mar 9, 2026

About N4 Pharma

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-cl... [Read more]

Sector Healthcare
Founded 1979
Employees 4
Stock Exchange London Stock Exchange AIM
Ticker Symbol N4P
Full Company Profile

Financial Performance

In 2024, N4 Pharma's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.

Financial Statements

News

There is no news available yet.